A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
← catalyst calendarNCT06915233 · readout ≤ 1,442 d
Sponsored by Vericel Corporation (industry) · VCEL — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
309estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-28 | actual | When the study began enrolling |
| Primary completion | Jul 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chondral Defect
- Articular Cartilage Defect
Interventions
- Biological: autologous cultured chondrocytes on porcine collagen membrane
- Procedure: Bone Marrow Stimulation
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 104 in the FAOS Pain and Function (SRA) subscale scores
measured Baseline to Week 104
Permalink · VCEL's whole pipeline · Catalyst calendar · Every registered study · What changed